Form 4: Snyder Mark Howard reports multiple insider transactions in HALO

Rhea-AI Filing Summary

Snyder Mark Howard reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 42,692 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 4,796 shares.

Insider Trade Summary

16,812 shares exercised/converted

Mixed 6 txns

Insider Snyder Mark Howard

Role SVP, CHIEF LEGAL OFFICER

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	4,796	$0.00	--
Exercise	Performance Stock Units	12,016	$0.00	--
Exercise	Common Stock	4,796	$0.00	--
Tax Withholding	Common Stock	2,587	$79.44	$206K
Exercise	Common Stock	12,016	$0.00	--
Tax Withholding	Common Stock	6,481	$79.44	$515K

Holdings After Transaction: Restricted Stock Units — 4,796 shares (Direct); Performance Stock Units — 0 shares (Direct); Common Stock — 38,977 shares (Direct)

Footnotes (1)

1. The reported disposition of 2,587 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. The reported disposition of 6,481 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/17/2026 - 06:53 PM Learn about SEC filing dates

FAQ

What insider activity did Halozyme (HALO) SVP Mark Snyder report on February 16, 2026?

Halozyme SVP Mark Snyder reported vesting of restricted and performance stock units on February 16, 2026, converting into common shares at a $0 exercise price. The filing also shows related share withholdings to satisfy tax obligations rather than open-market sales.

How many Halozyme (HALO) shares vested for Mark Snyder in this Form 4 filing?

The filing shows 4,796 shares from restricted stock units and 12,016 shares from performance stock units vesting into Halozyme common stock. Both awards converted at a $0 exercise price, reflecting equity compensation rather than cash-funded share purchases.

Were any of Mark Snyder’s Halozyme (HALO) shares sold on the open market?

The Form 4 does not show open-market sales. It reports dispositions of 2,587 and 6,481 shares classified as tax-withholding transactions, where the issuer withheld shares at $79.44 per share to cover Snyder’s tax liabilities on the vested awards.

What is Mark Snyder’s Halozyme (HALO) common stock ownership after these transactions?

After the reported vesting and tax-withholding dispositions, Mark Snyder directly beneficially owned 41,925 shares of Halozyme common stock. This figure reflects his remaining holdings after shares were withheld to satisfy tax obligations associated with the equity award settlements.

What do the ‘M’ and ‘F’ transaction codes mean in the Halozyme (HALO) Form 4?

Code “M” in the filing indicates the exercise or conversion of derivative securities, here the vesting of restricted and performance stock units into common stock. Code “F” indicates dispositions where shares were delivered or withheld to satisfy tax liabilities on those vested awards.

What prices are associated with Mark Snyder’s Halozyme (HALO) Form 4 transactions?

The equity awards converted into common stock at an exercise price of $0 per share. For the tax-withholding dispositions, the filing reports a price of $79.44 per share, the value used when shares were withheld to pay Snyder’s tax obligations on the vested stock units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Snyder Mark Howard

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF LEGAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/16/2026		M		4,796	A	$0	38,977	D
Common Stock	02/16/2026		F		2,587(1)	D	$79.44	36,390	D
Common Stock	02/16/2026		M		12,016	A	$0	48,406	D
Common Stock	02/16/2026		F		6,481(2)	D	$79.44	41,925	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	02/16/2026		M			4,796	(3)	(3)	Common Stock	4,796	$0	4,796	D
Performance Stock Units	$0	02/16/2026		M			12,016	(4)	(4)	Common Stock	12,016	$0	0	D

Explanation of Responses:

1. The reported disposition of 2,587 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

2. The reported disposition of 6,481 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

3. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

4. This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.